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Introduction
When the earliest clinical trials of the defined, quantified 
Ginkgo biloba extract EGb 761® and some other drugs, 
then called “nootropics”, were conducted during the 1970s 
and 1980s, there was no widely accepted diagnostic term, 
let alone consensus diagnostic criteria, for what was later 
called “ageing-associated cognitive decline” (AACD) [1], 
“cognitive impairment no dementia” (CIND) [2] or “mild 
cognitive impairment” (MCI) [3, 4]. For cognitive impair-
ment in the elderly, vaguely defined terms were often 
used, e.g.: “organic brain syndrome”, “cerebral insuffi-
ciency”, “impairment of cerebral performance”, “Hirn-
leistungsstörungen” (German), “troubles du vieillissement 
cérébral” (French) or, when associated with cerebrovascu-
lar disease, “cerebrovascular insufficiency”. The DSM-III 
[5] already provided a description and diagnostic criteria 
for dementia and research diagnostic criteria for Alzhei-
mer’s disease (AD) [6] and vascular dementia (VaD) [7] 
followed soon. The DSM criteria have been revised repeat-
edly (DSM-III-R [8]; DSM-IV [9]). In addition to the 
DSM criteria, the diagnostic criteria of the International 
Classification of Diseases (ICD-10) [10] were also used 
in clinical trials. A comparison of these sets of criteria is 
provided in Table 1. In spite of the availability of diagnos-
tic criteria and related nomenclature, there was continued 
reluctance among European clinicians to assign a diagno-
sis of dementia to a patient, as dementia was perceived as 
stigmatizing. Hence, descriptive terms that were neither 
precisely defined nor part of the thesaurus of a systematic 
classification of diseases were often used for conditions 
Abstract When the early trials of Ginkgo biloba extract 
EGb 761® were conducted, different terms were used to 
denote ageing-associated neurocognitive disorders. With 
the fifth edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5), a taxonomy covering dementia 
and pre-dementia stages of such disorders became avail-
able. DSM-5 diagnostic criteria for neurocognitive dis-
orders (NCDs) were applied to patients with any type of 
ageing-associated cognitive impairment, including demen-
tia, enrolled in randomized controlled clinical trials of EGb 
761®, taking into account the reported inclusion and exclu-
sion criteria and patient characteristics at baseline. For 23 
of 31 trials (74 %), the inclusion diagnoses could be clas-
sified as NCD in accordance with DSM-5. Thirteen tri-
als enrolled patients with major NCD, four trials enrolled 
patients with mild NCD and six trials enrolled patients 
with NCD, who could not be classified unambiguously as 
having mild or major NCD. Although various terms were 
formerly used for neurocognitive disorders, the patients 
enrolled in the majority of clinical trials with EGb 761® 
could be classified retrospectively using modern DSM-5 
diagnostic criteria.
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along the continuum of MCI and dementia until the end of 
the millennium. As a consequence, it was difficult to gauge 
whether patients enrolled in different clinical trials in fact 
had different disorders or whether different terms for the 
same disorder were being used in different publications.
Until recently, in contrast to dementia, the pre-dementia 
stages of neurocognitive disorders were poorly accounted 
for by disease classifications. Whereas the various types of 
dementia were classified as distinct entities with specific 
aetiologies in earlier editions of the DSM and the Inter-
national Classification of Diseases (ICD), a heterogene-
ous collection of conditions between healthy ageing and 
dementia was subsumed under the term MCI. It was only in 
2007 that Dubois and colleagues [11] took a “longitudinal” 
perspective when preparing a revision of the NINCDS-
ADRDA criteria for Alzheimer’s disease. They proposed 
prodromal or MCI stages corresponding to each aetiologi-
cally defined dementia disorder. Similarly, with the change 
from DSM-IV to DSM-5, the classification was refined to 
cover the whole range of disorders from clear-cut MCI to 
full-blown dementia under the category “neurocognitive 
disorders” (NCDs) [12]. There is now provision (although 
not a strict requirement) for aetiological differentiation 
within both “mild neurocognitive disorder” (representing 
the MCI stage) and “major neurocognitive disorder” (repre-
senting dementia). From an ethical point of view, it is note-
worthy that the new nomenclature no longer uses the term 
“dementia”, which has been perceived as pejorative and 
stigmatizing [13].
The question addressed by this research is to what extent 
the inclusion diagnoses and criteria applied in clinical trials 
of G. biloba extract EGb 761® fit within the new DSM-5 
taxonomy. Using published information and, as far as 
needed and available, unpublished data, we retrospectively 
classified the patients enrolled in randomized controlled tri-
als of EGb 761® in terms of DSM-5 diagnostic categories.
Methods
Published papers on all randomized controlled trials of 
EGb 761® in cognition-related ailments and disorders were 
retrieved. These were identified by a comprehensive lit-
erature search in the context of the call for scientific data 
on G. biloba for assessment by the Committee on Herbal 
Medicinal Products (HMPC) of the European Medicines 
Agency in October 2011. All available information about 
diagnostic terms, diagnostic criteria, inclusion and exclu-
sion criteria, presence and actual severity of cognitive and 
functional impairment at baseline was retrieved at study 
level and checked against the DSM-5 criteria for major 
NCD and mild NCD and their aetiological sub-classes. If 
an unambiguous classification was not possible from the 
published information, the original clinical trial reports 
were retrieved, as far as available, and information relevant 
to diagnostic classification was extracted at patient and 
study level, as appropriate.
Major NCD
The diagnosis of major NCD is based on four main cri-
teria, A–D, and two sub-criteria to criterion A (A1, A2). 
Criterion A requires a “significant cognitive decline from 
a previous level of performance in one or more cognitive 
domains”, evidence of which should be based on the two 
sub-criteria. A1 specifies that the “concern of the individ-
ual, a knowledgeable informant or the clinician” should be 
present; A2 “a substantial impairment in cognitive perfor-
mance”. Both A1 and A2 must be met. Furthermore, the 
following are also mandatory: interference of cognitive 
deficits “with independence in everyday activities” (cri-
terion B), occurrence not “exclusively in the context of a 
delirium” (criterion C) and that the “cognitive deficits are 
not better explained by another mental disorder” (criterion 
D).
In a substantial number of trials, the diagnosis of demen-
tia, probable AD, probable VaD or possible AD with cer-
ebrovascular disease (CVD) was established in accordance 
with DSM-III, DSM-III-R, ICD-10, NINCDS-ADRDA 
or NINDS-AIREN, as applicable. Therefore, the vari-
ous sets of diagnostic criteria used in the included studies 
were compared to determine how and to what extent cri-
teria of the DSM-5 correspond to criteria of the other clas-
sifications and whether fulfilment of DSM-5 criteria can be 
concluded from the fulfilment of corresponding criteria of 
other classifications. Additional information from inclusion 
and exclusion criteria, neuropsychological tests and rating 
scales supporting the diagnosis of major NCD was pre-
sented in the published reports on these trials.
If none of the sets of diagnostic criteria mentioned above 
was employed, all pertinent information, such as inclusion 
and exclusion criteria, means and distributions of actual 
test and rating scale scores, was utilized to check whether 
the criteria for major NCD were met.
Mild NCD
The diagnosis of mild NCD is also based on four main cri-
teria, A to D, and two sub-criteria to criterion A (A1, A2). 
Criterion A requires a “modest cognitive decline from a 
previous level of performance in one or more cognitive 
domains”, evidence of which should be derived from the 
two sub-criteria. A1 specifies that the “concern of the indi-
vidual, a knowledgeable informant or the clinician” should 
be present; A2 “a modest impairment in cognitive per-
formance”. Both A1 and A2 must be met. Moreover, it is 
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mandatory that the cognitive deficits “do not interfere with 
capacity for independence in everyday activities” (criterion 
B), “do not occur exclusively in the context of a delirium” 
(criterion C) and are “not better explained by another men-
tal disorder” (criterion D).
The consensus criteria for MCI [4] that were employed 
in one trial [14] explicitly cover criteria A (including A1 
and A2) and B. From the exclusion criteria reported in the 
published paper, it is evident that criteria C and D were also 
met by the enrolled patients. The eligibility criteria of the 
other trials with patients who were cognitively impaired 
but not demented were as variable as the diagnostic terms 
assigned. Hence, all available information was utilized to 
check whether the criteria for mild NCD were met.
Aetiological sub‑classes
Testing for AD genetic mutations or genetically determined 
vascular disorders was not performed in any of the studies, 
nor was a specific family history documented. Hence, the 
classification of NCD due to probable or possible AD was 
mainly based on the course of the disease [“insidious onset 
and gradual progression” (criteria B and C2b), “clear evi-
dence of decline in memory and learning” (criteria B and 
C2a)], lacking evidence of mixed aetiology (criterion C2c) 
and the fact that the disturbance is not better explained by 
another disorder (criterion D).
The classification of vascular NCD mainly relies on the 
temporal relationship of its onset to one or more cerebro-
vascular events (criterion B1) or evidence for a promi-
nent decline in complex attention and frontal-executive 
function (criterion B2), evidence of the presence of cer-
ebrovascular disease (criterion C) and the fact that the 
symptoms are not better explained by another disorder 
(criterion D). In the absence of genetic testing, the prob-
ability of vascular origin is assessed by neuroimaging and 
the temporal relationship with one or more cerebrovascu-
lar events.
The NINCDS-ADRDA criteria for probable Alzheimer’s 
disease cover the DSM-5 criteria A, B, C2 and D for major 
NCD due to probable Alzheimer’s disease. The NINDS-
AIREN criteria cover the DSM-5 criteria A, B1, C and 
D and the probability criterion 2 for probable major vas-
cular NCD. Possible AD (NINCDS-ADRDA) with CVD 
(NINDS-AIREN) can be classified under major NCD due 
to multiple aetiologies (specifically AD and CVD). In all 
trials that used the NINCDS-ADRDA and/or NINCDS-
AIREN criteria, further information supporting the aetio-
logical sub-classification was available from neuroimaging.
In studies not employing NINCDS-ADRDA and/or 
NINDS-AIREN criteria, all available information was uti-
lized to check whether the DSM-5 criteria for aetiological 
sub-categories were met.
Results
A total of 31 randomized controlled trials of G. biloba 
extract EGb 761® in elderly patients with various degrees 
of cognitive impairment were identified. The inclusion 
diagnoses of 23 trials (74 %) could be classified as NCD. 
In four trials, the presence of NCD was likely, but could not 
be ascertained beyond doubt, and in four trials, the criteria 
for NCD were not met.
Studies in major NCD
The diagnostic criteria for major NCD or dementia of the 
classifications used in the included trials are presented in 
Table 1, arranged in a way to highlight the features in com-
mon and the differences. Some salient differences are: (a) 
only DSM-5 specifies that “the individual, a knowledge-
able informant or the clinician” has to show concern about 
the cognitive decline; (b) DSM-5 requires deficits in one 
or more domains, whereas all other sets of criteria require 
impairment in at least two or even more than two (NINDS-
AIREN) domains; (c) DSM-5 is the only classification 
that allows a diagnosis of dementia without overt memory 
impairment—“unusual nonamnestic presentations… also 
exist”; (d) the NINCDS–ADRDA criteria do not explic-
itly mention interference with activities of daily living, but 
presence of dementia is required, with “dementia” usually 
being understood as cognitive decline severe enough to 
interfere with professional and/or social activities.
The DSM-5 criteria A2, B and C could be assumed to 
be met if any of the other classifications listed in Table 2 
was used in a study. Fulfilment of criterion A1 was usu-
ally concluded from the patients seeing a clinician and 
undergoing examinations and diagnostic procedures. The 
DSM-III-R criteria for dementia in general do not explic-
itly require that there be a decline in cognitive abilities 
(criterion A), but the explanatory text mentions a loss in 
intellectual abilities and the criteria for both AD and MID 
require deterioration in cognitive performance in order to 
establish the diagnosis. The ICD-10 criterion G4, speci-
fying that the cognitive decline should have been present 
for at least 6 months for a confident diagnosis of demen-
tia, seems to have a similar intention, but is not explicit in 
saying that there should be no better explanation for the 
cognitive deficits than dementia. The ICD-10 criteria were 
used in one of the included studies, and the patients of this 
study also had to meet the DSM-III-R criteria. Overall, it 
can be concluded that all patients diagnosed with demen-
tia using one of the sets of criteria listed in Table 1 can 
safely be classified as having major NCD in accordance 
with DSM-5.
Thirteen trials (42 %) enrolled patients that could be 
classified unambiguously as having major NCD. In nine of 
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these trials the aetiological sub-classifications also meet the 
criteria set by DSM-5 (Table 2), in three trials the aetiologi-
cal sub-classification could not be confirmed beyond doubt, 
and in one trial no sub-classification was made (Table 3). 
If more than one aetiological category was acceptable for 
a trial, the aetiological sub-classification was always made 
prospectively.
Studies in major or mild NCD
Six trials (19 %) enrolled patients who could be classified 
unambiguously as having NCD, but interference of the 
cognitive deficits with independence in everyday activities 
(criterion B) was not completely clear (Table 4). Hence, no 
strict distinction between mild NCD and major NCD can 
be made. In two of these studies, the DSM-5 criteria for 
possible vascular NCD are fulfilled.
Studies in mild NCD
Patients meeting DSM-5 criteria for mild NCD were 
enrolled in four trials (13 %) (Table 5). No aetiological 
sub-classification was made in these trials.
Studies in patients not classified by DSM‑5
Eight studies (26 %) enrolled patients who could not be 
classified unambiguously as having NCD in accordance 
with DSM-5 diagnostic criteria (Table 6). This does not 
necessarily mean that these patients did not have NCD; it 
Table 3  Studies of EGb 761® that enrolled patients with major NCD, aetiological sub-classification not entirely certain or not made
a Patients were diagnosed in accordance with NINCDS-ADRDA criteria, but the authors did not specify whether probable AD or possible AD or 
both were accepted
b The inclusion diagnosis assigned by the clinician was “primary degenerative dementia”, which was then used synonymously with dementia 
of the Alzheimer type, but diagnostic criteria were not specified. Hence, not all DSM-5 criteria for aetiology could be verified. The acceptable 
range for the Hachinski Ischaemic Score (up to 7) supports the clinical diagnosis of Alzheimer’s disease, but does not strictly exclude mixed AD/
vascular aetiology
GDS Global Deterioration Scale, KAI Kurztest für Allgemeine Intelligenz (Short Test for General Intelligence), MMSE Mini-Mental State Exam-
ination, NAA Nürnberger Alters-Alltags-Skala (Nuremberg Gerontopsychological Self-Rating Scale for Activities of Daily Living), NAB Nürn-
berger Alters-Beobachtungs-Skala (Nuremberg Gerontopsychological Observation Scale for Activities of Daily Living), NAI Nürnberger Alters-
Inventar (Nuremberg Gerontopsychological Inventory), SCAG Sandoz Clinical Assessment-Geriatric, WAIS Wechsler Adult Intelligence Scale
Author (year of publication) Diagnostic criteria  
used in the study
Tests for cognitive impairment  
and ADL/functional scales used  
to support diagnosis
DSM-5 diagnoses assigned retro-
spectively
Rai 1991 [30] NINCDS-ADRDA MMSE, Kendrick battery for the 
detection of dementia
Major NCD due to ADa
Haase 1996 [31] DSM-III-R MMSE, GDS, KAI, NAB, NAA Major NCD due to probable AD, 
possible vascular major NCD
Weitbrecht and Jansen 1986 [32] Not specified WAIS digit symbol substitu 
tion test, WAIS digit span test, 
SCAG, Crichton Geriatric Scale
Major NCD (most likely due to 
AD)b
Oswald 1997 [33] DSM-III SCAG, NAI Major NCD (no aetiological sub-
classification was made)
Table 4  Studies of EGb 761® that accepted patients with NCD without clear distinction between major NCD and mild NCD
a The inclusion diagnosis assigned by the clinician was “senile dementia of the Alzheimer type”, but diagnostic criteria are not specified. Hence, 
not all DSM-5 criteria could be verified. According to inclusion criteria and data recorded at baseline, more than 75 % of patients had major 
NCD, for 25 % this could not be verified beyond doubt. Cognitive deficits, Hachinski Ischaemic Score and CT scan support the clinical diagno-
sis of Alzheimer’s disease
Author (year of publication) DSM-5 diagnoses
Gräßel 1992 [34] Possible vascular major NCD, possible vascular mild NCD
Halama 1988 [35] Possible vascular major NCD, possible vascular mild NCD
Hofferberth 1994 [36] Major NCD, mild NCD (aetiological sub-classification uncertain)a
Schubert and Halama 1993 [37] Major NCD, mild NCD (no aetiological sub-classification was made)
Israël 1987 [38] Major NCD, mild NCD (no aetiological sub-classification was made)
Wesnes 1987 [39] Major NCD, mild NCD (no aetiological sub-classification was made)
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only means that the information provided was not sufficient 
to safely conclude that all included patients had NCD.
Discussion
Using available diagnostic and other descriptive informa-
tion, predominantly from published papers, the patients 
of most (74 %) randomized controlled trials of G. biloba 
extract EGb 761® could be classified in terms of the new 
DSM-5 diagnostic categories. As expected, a high propor-
tion of trials in major NCD (nine out of 13) allowed an 
unambiguous aetiological sub-classification at the “proba-
ble” level (Table 2); in three trials the level of certainty was 
lower than “probable”, and only one trial in major NCD did 
not classify the patients by aetiology (Table 3). In contrast, 
no aetiological sub-classification was made in the four tri-
als enrolling only patients with mild NCD (Table 5). This 
reflects the presence of aetiological sub-classes for demen-
tia, but not for pre-dementia stages of cognitive impair-
ment, in earlier classifications of mental disorders. For two 
of the six trials that admitted both major NCD and mild 
NCD, an unambiguous classification as vascular NCD was 
possible, and for another one a classification as NCD due to 
AD was reasonably likely.
Using mainly inclusion and exclusion criteria and sever-
ity information at study level for classification, a patient 
sample was classified under mild or major NCD and 
under an aetiological sub-group only if all patients met the 
respective criteria. Our procedure can therefore be regarded 
as conservative. If the inclusion diagnosis in terms of mild 
or major NCD or aetiology could not be ascertained for 
the whole study sample, this study population remained 
unclassified with respect to mild or major NCD (Table 4) or 
with respect to aetiology (Table 3).
The new DSM-5 concept integrates the early (pre-
dementia) and later (dementia) stages of aetiologically 
different neurocognitive disorders with the common core 
feature “cognitive decline” within one common framework. 
The studies that admitted both patients with mild NCD and 
those with major NCD reflect a problem that has not been 
resolved completely by the DSM-5, i.e. a precise defini-
tion and operationalization of interference of the cognitive 
deficits with independence in everyday activities. Since 
the 1980s, the distinction between MCI and dementia or 
mild NCD and major NCD has been refined considerably, 
yet room for interpretation still remains. Interestingly, the 
Herbal Medicinal Products Committee (HMPC) of the 
European Medicines Agency (EMA) overcame this prob-
lem by phrasing the therapeutic indication for well-estab-
lished use of G. biloba leaf extract as follows: “improve-
ment of (age-associated) cognitive impairment and of 
quality of life in mild dementia” [15]. It thus acknowl-
edges that there is evidence of efficacy from randomized 
Table 5  Studies of EGb 761® 
that enrolled only patients with 
mild NCD
Author (year of publication) DSM-5 diagnoses
Gavrilova 2014 [14] Mild NCD (no aetiological sub-classification was made)
Grass-Kapanke 2011 [40] Mild NCD (no aetiological sub-classification was made)
Allain 1993 [41] Mild NCD (no aetiological sub-classification was made)
Stocksmeier and Eberlein 1992 [42] Mild NCD (no aetiological sub-classification was made)
Table 6  Studies of EGb 
761® enrolling patients not 
classifiable by DSM-5
a The main inclusion diagnosis was AAMI, which could be mild NCD; a small proportion of patients 
were assigned a diagnosis of dementia applying DSM-III-R and ICD-10 criteria by nursing home staff not 
trained to diagnose dementia. The SKT scores were in the range typical for mild-to-moderate dementia, 
which renders the high rate of AAMI questionable. On the other hand, interference with activities of every-
day life was denied for most patients. In the absence of laboratory tests and neuroimaging, the possibility 
of conditions other than AAMI or dementia must be taken into account and any classification in terms of 
NCD would be imprudent
Author (year of publication) Original diagnosis
van Dongen 2003 [43] Age-associated memory impairment (AAMI), dementiaa
Hofferberth 1991 [44] Organic brain syndrome with increased vascular risk
Halama 1990 [45] Cerebrovascular insufficiency
Hofferberth 1989 [46] Organic brain syndrome
Taillandier 1986 [47] Chronic cerebral insufficiency
Eckmann and Schlag 1982 [48] Cerebrovascular insufficiency
Dieli 1981 [49] Chronic cerebral insufficiency
Moreau 1975 [50] Chronic insufficiency of cerebral circulation
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controlled trials in both MCI and dementia or, in other 
words, mild NCD and major NCD.
By re-grouping patient samples of older studies in terms 
of DSM-5 diagnostic categories, well-defined and widely 
accepted diagnoses could be assigned to the patients of a 
considerable number of clinical trials in which old-fash-
ioned and vaguely defined diagnostic terms were origi-
nally used. This does not immediately change the overall 
knowledge base concerning the efficacy of EGb 761®, but 
it enables comparisons between studies of different periods 
in time and appropriate aggregation of trials for system-
atic reviews and meta-analyses. As recently accomplished 
for dementia [16], a meta-analysis can now be conducted 
across studies of patients with mild NCD. The new clas-
sification also helps younger clinicians and researchers 
understand which types of patients were enrolled in studies 
conducted more than two decades ago.
Interestingly, a comparison of various sets of diagnostic 
criteria for dementia and major NCD found a high concord-
ance, allowing a DSM-5 diagnosis of major NCD in a high 
proportion of patients who were diagnosed with dementia 
according to the older classifications. There is, however, 
no complete congruence between the classifications, with 
DSM-5 tending to be more inclusive than earlier classifica-
tions. Patients diagnosed, e.g. as having major NCD due to 
probable AD or probable vascular major NCD by DSM-5, 
would not necessarily meet the more elaborate NINCDS-
ADRDA criteria for probable AD or NINDS-AIREN crite-
ria for probable VaD.
Using the DSM-5 diagnostic term “neurocognitive dis-
order”, where appropriate, helps overcome some of the 
problems associated with the use of terms such as “demen-
tia” or (cerebral, cerebrovascular) “insufficiency”, which 
are widely perceived as stigmatizing and devaluing [13, 
17]. First, dementia (defined as deterioration or loss of the 
intellectual faculties, the reasoning power, the memory, and 
the will [18]) is an inappropriate term for the early stages 
of NCDs during which full independence or at least a large 
capacity to manage everyday life is retained. Second, a 
considerable number of family physicians are still reluctant 
to diagnose dementia and to communicate this diagnosis to 
patients and their families, due to the stigma associated not 
only with the disease itself, but with the term dementia in 
particular [17, 19]. On the other hand, the change in termi-
nology implemented by psychiatrists, but not neurologists 
(e.g. NINCDS-ADRDA revision [11]; NIA-AA criteria 
[20]) may render communication and collaboration of neu-
rologists and psychiatrists in the field of neurodegenerative 
diseases more difficult.
It is a particular strength of our research that DSM-5 
diagnoses were assigned only if the available informa-
tion permitted the verification of all pertinent diagnostic 
criteria for the whole patient sample. This means that the 
patients classified retrospectively met the same criteria 
as those that patients enrolled in clinical trials today are 
required to meet. A limitation is the retrospective approach, 
because the interpretation of today’s DSM-5 criteria may 
not be exactly the same as the interpretation of correspond-
ing inclusion criteria stipulated 20 years ago. Moreover, 
increased awareness of the risk of developing NCD and 
refined diagnostic procedures may lead to higher propor-
tions of very mildly affected patients in today’s special-
ized centres that recruit patients to clinical trials. However, 
similar variability between patient samples from different 
trials is to be expected even in the case of prospective diag-
nosis. This is likely to result from differences in the types 
of patients available at different clinical sites and the pos-
sibility of some diversity in interpretation of the diagnostic 
criteria in various regions with different cultures.
In conclusion, the new classification and nomenclature 
of the DSM-5 could be applied successfully to assign mod-
ern, consistent and meaningful diagnostic terms to elderly 
patients with cognitive impairments enrolled in clinical 
trials over the past two and a half decades. The patients 
of 74 % of the randomized controlled trials of G. biloba 
extract EGb 761® identified by a comprehensive litera-
ture search could be retrospectively classified by matching 
selection criteria and baseline data to the DSM-5 diagnostic 
criteria.
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